These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16514715)

  • 1. Reversible posterior leukoencephalopathy syndrome and bevacizumab.
    Ozcan C; Wong SJ; Hari P
    N Engl J Med; 2006 Mar; 354(9):980-2; discussion 980-2. PubMed ID: 16514715
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversible posterior leukoencephalopathy syndrome and bevacizumab.
    Glusker P; Recht L; Lane B
    N Engl J Med; 2006 Mar; 354(9):980-2; discussion 980-2. PubMed ID: 16510760
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
    Allen JA; Adlakha A; Bergethon PR
    Arch Neurol; 2006 Oct; 63(10):1475-8. PubMed ID: 17030665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
    Mir O; Mouthon L; Alexandre J; Mallion JM; Deray G; Guillevin L; Goldwasser F
    J Natl Cancer Inst; 2007 Jan; 99(1):85-6. PubMed ID: 17202119
    [No Abstract]   [Full Text] [Related]  

  • 5. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
    Heinzerling JH; Huerta S
    Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab.
    Levy CF; Oo KZ; Fireman F; Pierre L; Bania MA; Sadanandan S; Yamashiro DJ; Glade Bender JL
    Pediatr Blood Cancer; 2009 May; 52(5):669-71. PubMed ID: 19101996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion.
    Mavragani CP; Vlachoyiannopoulos PG; Kosmas N; Boletis I; Tzioufas AG; Voulgarelis M
    Rheumatology (Oxford); 2004 Nov; 43(11):1450-1. PubMed ID: 15501998
    [No Abstract]   [Full Text] [Related]  

  • 8. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.
    El Maalouf G; Mitry E; Lacout A; Lièvre A; Rougier P
    J Neurol; 2008 Feb; 255(2):295-6. PubMed ID: 18283405
    [No Abstract]   [Full Text] [Related]  

  • 9. Bevacizumab-associated reversible hypotension.
    Iqbal K; Chu Q; Mei Q; Chen Y
    Clin Oncol (R Coll Radiol); 2007 Dec; 19(10):800-1. PubMed ID: 17825542
    [No Abstract]   [Full Text] [Related]  

  • 10. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
    Abbas O; Shamseddin A; Temraz S; Haydar A
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23436889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posterior reversible encephalopathy syndrome with bevacizumab.
    Lau PC; Paunipagar B
    Hong Kong Med J; 2011 Feb; 17(1):80-1. PubMed ID: 21282833
    [No Abstract]   [Full Text] [Related]  

  • 12. [Bevacizumab therapy for Poems syndrome].
    Doffoel-Hantz V; Jaccard A; Sparsa A; Girault S; Bonnetblanc JM; Bordessoule D; Bédane C
    Ann Dermatol Venereol; 2008 Apr; 135(4):320-1. PubMed ID: 18420085
    [No Abstract]   [Full Text] [Related]  

  • 13. [Reversible posterior leukoencephalopathy syndrome associated to bevacizumab].
    Ortiz-Lopez EM; Gonzalez-Nieto JA; Rojas-Marcos I; Blanco-Ollero A
    Rev Neurol; 2010 Jul; 51(2):117-8. PubMed ID: 20602317
    [No Abstract]   [Full Text] [Related]  

  • 14. Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome.
    Smith AR; Hennessy JM; Kurth MA; Nelson SC
    Pediatr Blood Cancer; 2008 Sep; 51(3):418-20. PubMed ID: 18493993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension.
    Dincer M; Altundag K
    Ann Pharmacother; 2006 Dec; 40(12):2278-9. PubMed ID: 17105834
    [No Abstract]   [Full Text] [Related]  

  • 16. Papulopustular eruption after intravitreal bevacizumab (Avastin).
    Amselem L; Diaz-Llopis M; Garcia-Delpech S; Montero J; Palomares P; Cervera E
    Acta Ophthalmol; 2009 Feb; 87(1):110-1. PubMed ID: 18577190
    [No Abstract]   [Full Text] [Related]  

  • 17. [Bevacizumab and lung cancer: eligible patients in daily practice].
    Lagnien-Gaume V; Jehl J; Manzoni P; Jacoulet P; Gainet-Brun M; Metzger F; Pernet D; Polio JC; Pugin JF; Corgne J; Amoros C; Dalphin JC; Westeel V
    Rev Mal Respir; 2011 Jan; 28(1):25-31. PubMed ID: 21277471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible posterior encephalopathy syndrome associated with bortezomib.
    Terwiel E; Hanrahan R; Lueck C; D'Rozario J
    Intern Med J; 2010 Jan; 40(1):69-71. PubMed ID: 20561367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible posterior leukoencephalopathy syndrome.
    Norden AD; Batchelor TT
    Onkologie; 2007 Mar; 30(3):90-1. PubMed ID: 17341892
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic adverse events after bevacizumab.
    Roth DB; King A; Weiss M; Klein D
    Ophthalmology; 2009 Jun; 116(6):1226.e1. PubMed ID: 19486800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.